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Introduction: The role of reactive carbonyl species, such as methylglyoxal (MG), has been overlooked within the
context of the sepsis syndrome. The aims of this study were to assess the impact of MG formation in different
inflammatory settings and to evaluate its use for early diagnosis as well as prognosis of the sepsis syndrome.
Methods: In total, 120 patients in three groups were enrolled in this observational clinical pilot study. The three
groups included patients with septic shock (n = 60), postoperative controls (n = 30), and healthy volunteers (n = 30).
Plasma samples from patients with septic shock were collected at sepsis onset and after 24 hours and 4, 7, 14, and
28 days. Plasma samples from postoperative controls were collected prior to surgery, immediately following the
end of the surgical procedure as well as 24 hours later and from healthy volunteers once. Plasma levels of MG were
determined by high-performance liquid chromatography. Additionally, plasma levels of procalcitonin, C-reactive
protein, soluble CD14 subtype, and interleukin-6 were determined.
Results: Patients with septic shock showed significantly higher plasma levels of MG at all measured times, compared
with postoperative controls. MG was found to identify patients with septic shock more effectively—area under the
curve (AUC): 0.993—than procalcitonin (AUC: 0.844), C-reactive protein (AUC: 0.791), soluble CD14 subtype (AUC: 0.832),
and interleukin-6 (AUC: 0.898) as assessed by receiver operating characteristic (ROC) analysis. Moreover, plasma levels of
MG in non-survivors were significantly higher than in survivors (sepsis onset: *P = 0.018 for 90-day survival; **P = 0.008
for 28-day survival). Plasma levels of MG proved to be an early predictor for survival in patients with septic shock (sepsis
onset: ROC-AUC 0.710 for 28-day survival; ROC-AUC 0.686 for 90-day survival).
Conclusions: MG was identified as a marker for monitoring the onset, development, and remission of sepsis and was
found to be more useful than routine diagnostic markers. Further studies are required to determine the extent of MG
modification in sepsis and whether targeting this pathway could be therapeutically beneficial to the patient.
Trial registration: German Clinical Trials Register DRKS00000505. Registered 8 November 2010.Introduction
Sepsis represents an ongoing challenge in intensive care
units (ICUs) and remains the most common cause of
mortality in this setting [1,2]. Increased oxidative stress,
as a consequence of the systemic inflammatory response,
has been suggested as a major causative factor for the
development and progression of the disease. However,* Correspondence: thorsten.brenner@med.uni-heidelberg.de
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with antioxidants in patients with sepsis could be benefi-
cial [3,4]. This may suggest the involvement of alternative
mediators of cellular stress in the pathophysiology of
sepsis.
Reactive carbonyl species (RCS) have emerged as effect-
ive mediators of cellular dysfunction. RCS are a heteroge-
neous group of reactive low-molecular-weight carbonyls,
which are able to interact with various biomolecules, such
as proteins, deoxyribonucleic acid, or phospholipids,
resulting in structural distortions and functional impair-
ment [5]. The detrimental effects of RCS are comparablel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Characteristics of 60 patients in the septic group
Septic group (n = 60)
Demographic data
Age, years 70 (64-76)
Male sex 46 (76.7%)
ASA status: I; II; III; IV; V 1 (1.7%); 11 (18.3%); 29 (48.3%);
15 (25.0%); 1 (1.7%)
Primary site of infection (double-naming feasible)
Lung 12 (20.0%)
Gastrointestinal tract 32 (53.3%)




Gram-positive isolates 16 (26.7%)
Gram-negative isolates 16 (26.7%)





Septic shock 60 (100.0%)
Acute renal failure 35 (58.3%)
Acute respiratory distress syndrome 49 (81.2%)
Acute liver failure 15 (25.0%)
Disease severity scoring S/T0 S/T1
APACHE II score 33 (27-38) 33 (28-39)
SAPS 75 (66-86) 73 (64-84)
SOFA score 14 (11-15) 14 (12-15)
Clinical data S/T0 S/T1
Norepinephrine, μg/kg per minute 0.20 (0.06-0.31) 0.20 (0.08-0.32)
Maximum heart rate, 1/minute 115 (97-130) 113 (102-127)
Minimum MAP, mm Hg 57 (50-64) 60 (54-66)
FiO2, none 0.65 (0.50-0.80) 0.58 (0.46-0.70)
Data are presented as number (percentage) or as median (with quartiles).
APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA status,
physical status classification system according to the American Society of
Anesthesiologists; FiO2, fraction of inspired oxygen; MAP, mean arterial
pressure; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ
Failure Assessment.
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that RCS are significantly more stable and can readily dif-
fuse out of the cell and have effects far from the original
site of their formation [5]. Furthermore, several of the
most reactive RCS are derived from glucose metabolism
(in particular, glycolysis) [5]. As ROS require three stages
of metabolism before they are produced, RCS can be
viewed as providing a more direct insult to the macromol-
ecular integrity of the cell.
Methylglyoxal (MG) is a highly reactive RCS, produced
endogenously from the spontaneous degradation of trio-
sephosphates—glyceraldehyde-3-phosphate (GA3P) and
dihydroxyacetone phosphate (DHAP)—during glycolysis.
It is estimated that approximately 0.089% of triosepho-
sphates are converted to MG and that the total body
rate of formation for a healthy adult human is about
3 mmol per day [6]. The formation of MG is closely
linked to the rate of glycolysis within the cell. It would
be expected that under physiological conditions, where
there is either an increase in glycolytic flux or an in-
creased dependence on glycolysis for energy, the rate of
MG formation would be increased [7,8]. This has proven
to be the case in patients with diabetes mellitus, in
which complications such as nephropathy, neuropathy,
and retinopathy can be linked to increases in cellular
levels of glycated proteins, which then are referred to as
advanced glycation end products (AGEs) [9].
A clinical feature of patients with sepsis is hyperglycemia
[10,11]. However, the consequences of elevated blood glu-
cose in sepsis, particularly with respect to production of
MG and its potential role in the development and progres-
sion of the disease, have yet to be fully investigated. The
aims of this study were to assess the impact of MG forma-
tion in different inflammatory settings and to evaluate its
use for early diagnosis as well as prognosis of sepsis.
Materials and methods
Selection of patients and study procedures
The observational clinical pilot study was approved by
the local ethics committee (Ethics Committee of the
Medical Faculty of Heidelberg: Trial Code Number S123-
2009/German Clinical Trials Register: DRKS00000505)
and was conducted in the surgical ICU of the University
Hospital of Heidelberg, Germany. Study and control pa-
tients or their legal designees provided written informed
consent. In total, 120 patients in three groups were con-
secutively enrolled into the study from August 2009 to
July 2010. The three groups were the following: (1) 60 pa-
tients with septic shock, according to the criteria of the
International Sepsis Definitions Conference [12] (referred
to as the septic group, or S) (Table 1), due to documented
or suspected infection according to the criteria of the
International Sepsis Forum Consensus Conference on Def-
initions of Infection in the ICU (Additional file 1: Table S1)[13]; (2) 30 postoperative controls following major ab-
dominal surgery without any evidence of infection (the
postoperative group, or P) (Table 2); and (3) 30 healthy
volunteers (the volunteer group, or V) (Table 2). Blood
samples from patients with septic shock were collected at
sepsis onset (T0) and 24 hours (T1), 4 days (T2), 7 days
(T3), 14 days (T4), and 28 days (T5) later. Blood samples
from the postoperative group were collected prior to sur-
gery (T0), immediately following the end of the surgical
procedure (T1), and 24 hours later (T2). Blood samples
from the volunteer group were collected once (T0).
Table 2 Characteristics of 30 patients in the postoperative
group and 30 individuals in the volunteer group
Postoperative group (n = 30)
Demographic data
Age, years 62 (57-70)
Male sex 16 (53.3%)
ASA status: I; II; III; IV; V 0 (0.0%); 9 (30.0%); 20 (66.7%);
1 (3.3%); 0 (0.0%)




Volunteer group (n = 30)
Demographic data
Age, years 26 (24-28)
Male sex 19 (63.3%)
ASA status: I; II; III; IV; V 21 (70.0%); 9 (30.0%); 0 (0.0%);
0 (0.0%); 0 (0.0%)
Data are presented as number (percentage) or as median (with quartiles). ASA
status, physical status classification system according to the American Society
of Anesthesiologists.
Brenner et al. Critical Care  (2014) 18:683 Page 3 of 11Immunoassays
Plasma concentrations of total antioxidant capacity (TAC),
methylglyoxal-derived advanced glycation end products
(MG-AGE), and interleukin-6 (IL-6) were measured by
using enzyme-linked immunosorbent assay (ELISA) kits
in accordance with the instructions of the manufacturer
(TAC and MG-AGE: Biocat, Heidelberg, Germany; IL-6:
R&D Systems, Minneapolis, MN, USA). Plasma levels of
soluble CD14 subtype (sCD14-ST) were measured by
using the Pathfast Presepsin chemiluminescent enzyme
immunoassay in accordance with the instructions of the
manufacturer (Mitsubishi Chemical, Tokyo, Japan).Methylglyoxal measurements with high-performance
liquid chromatography
The concentrations of MG in plasma were determined
by derivatization with 1,2-diamino-4,5-dimethoxybenzene
and high-performance liquid chromatography of the qui-
noxaline adduct by fluorescence detection [14,15].Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated immediately after blood collection. Ethylenediamine-
tetraacetic acid (EDTA)-anticoagulated whole blood was
loaded carefully onto a lymphocyte separation medium
(PAA Laboratories GmbH, Pasching, Austria) and centri-
fuged for 25 minutes at 1,200 rpm without brakes at 4°C.
The PBMC-containing band was aspirated, and the cells
were washed three times with NaCl 0.9%.RNA extraction and quantitative polymerase chain reaction
RNA extraction was performed by using the column-
based RNeasy Plus Mini Kit (Qiagen, Hilden, Germany)
in accordance with the instructions of the manufacturer.
RNA (250 ng) was reverse-transcribed by using the
QuantiTect Reverse Transcription Kit (Qiagen) in ac-
cordance with the instructions of the manufacturer. Sub-
sequent real-time polymerase chain reaction (PCR)
analysis was performed on a StepOnePlus PCR cycler
(Applied Biosystems, Weiterstadt, Germany) by using
predesigned TaqMan assays for glyoxalase-1 (GLO-1)
(assay ID Hs00198702_m1) and β-Actin (assay ID
Hs99999903_m1). PCRs were set up by using the Taq-
Man Universal PCR Master Mix (Applied Biosystems,
Weiterstadt, Germany). All experiments were run in
triplicate. Results are interpreted by calculating the
change in cycle threshold (ΔCt) value (Ct β-actin – Ct
GLO-1) of each sample.
Statistical analysis
The present clinical investigation was conducted as a
pilot study. Group sizes were set at 60 individuals in the
septic group and 30 individuals in both the healthy and
postoperative groups. Resulting study data was entered
into an electronic database (Microsoft Excel 2010,
Microsoft Corporation, Redmond, WA, USA) and evalu-
ated by using SPSS software (Statistical Product and Ser-
vices Solutions, Version 20.0, SPSS Inc., Chicago, IL,
USA) or Graphpad Prism for Macintosh (Version 5.0f,
GraphPad Software, San Diego, CA, USA). Categorical
data were summarized by means of absolute and relative
frequencies. Quantitative data were summarized by
using medians (with quartiles). Wherever appropriate,
data was visualized by using line or bar charts. The
Kolmogorov-Smirnov test was applied to check for nor-
mal distribution. Owing to non-normally distributed
data in this study, non-parametric methods for evalu-
ation were used. Furthermore, a receiver operating char-
acteristic (ROC) curve was calculated with suitable
parameters in order to create cutoff values to determine
the diagnostic or prognostic value of each parameter
with regard to the diagnosis as well as the prognosis of
sepsis. Comparisons of the areas under two or more cor-
related ROC curves were performed as described by
Delong et al. [16]. Correlation analysis was performed
calculating Spearman-Rho (r). A P value of less than
0.05 was considered statistically significant. The follow-
ing symbols were used with regard to higher orders of
significance: *P <0.05, **P <0.01, ***P <0.001.
Results
In total, 120 patients in three groups were subjected for
evaluation. A detailed characterization of the different
groups is presented in Tables 1 and 2.
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human sepsis
In patients with septic shock (n = 60), plasma concentra-
tions of MG were significantly increased in comparison
with healthy volunteers (n = 30) (Figure 1a) and com-
pared with postoperative controls (n = 30) (Figure 1b).
Similar observations could be made for other routine in-
fection and inflammation markers such as C-reactiveFigure 1 Plasma levels of methylglyoxal in different inflammatory settin
in healthy volunteers (n = 30, white bar) and patients with septic shock (n = 6
patients with septic shock are presented at sepsis onset (S/T0) and 24 hours (
Plasma methylglyoxal measurements in healthy volunteers were performed o
confidence intervals (CIs). With regard to symbolism and higher orders of sign
healthy volunteers and patients with septic shock at the presented time points
controls following major abdominal surgery (n = 30, white-striped bars in blac
color). Plasma levels of methylglyoxal in patients with septic shock are presen
measurements in postoperative controls are presented immediately after the
in bar charts are presented as medians and 95% CIs. With regard to symbolismprotein (CRP), procalcitonin (PCT), IL-6, and sCD14-ST
(Table 3 and Additional file 2: Table S2). However, MG
proved to be superior for the identification of patients
with septic shock (S/T0 versus P/T2) as assessed by area
under the curve (AUC) comparisons of the related ROC
curves (Figure 2 and Table 4). Besides, plasma levels of
MG were shown to be independent of the septic focus
(lung, gastrointestinal tract, genitourinary tract, and sogs in humans. (a) Comparison of plasma methylglyoxal measurements
0, white-spotted bars in black color). Plasma levels of methylglyoxal in
S/T1), 4 days (S/T2), 7 days (S/T3), 14 days (S/T4), and 28 days (S/T5).
nce (V/T0). Data in bar charts are presented as medians and 95%
ificance: ***P <0.001. Asterisks refer to pairwise comparisons between
. (b) Comparisons of plasma methylglyoxal measurements in postoperative
k color) and patients with septic shock (n = 60, white-spotted bars in black
ted at sepsis onset (S/T0) and 24 hours (S/T1) later. Plasma methylglyoxal
end of the surgical procedure (P/T1) and 24 hours afterwards (P/T2). Data
and higher orders of significance: ***P <0.001.
Table 3 Plasma levels of C-reactive protein, procalcitonin, interleukin-6, soluble CD14 subtype, blood glucose, and total
antioxidant capacity in the volunteer (V/T0), postoperative (P/T0, P/T1, P/T2), and septic (S/T0, S/T1) groups
Parameters Volunteer group (n = 30) Postoperative group (n = 30) Septic group (n = 60)
V/T0 P/T0 P/T1 P/T2 S/T0 S/T1
CRP, mg/L 2.0 4.3 *** 4.3 *** 110.2 *** 169.2 *** 190.4 ***
PCT, μg/L 0.06 0.07 ns 0.10 ** 0.82 *** 4.63 *** 7.17 ***
IL-6, pg/mL 0.0 0.0 ** 215.3 *** 132.5 *** 500.5 *** 337.6 ***
sCD14-ST, pg/mL 123.0 208.5 *** 711.0 *** 680.0 *** 1817.5 *** 2309.0 ***
Blood glucose, mg/dL 85.0 102.5 ** 140.0 *** 116.0 *** 128.5 *** 139.0 ***
TAC, mM 0.02 0.06 *** 0.10 *** 0.12 *** 0.15 *** 0.13 ***
Data are presented as medians. Results of pairwise comparisons refer to intergroup comparisons of each presented time point in the postoperative (P/T0, P/T1, P/T2)
and septic (S/T0, S/T1) groups with the volunteer group (V/T0). With regard to symbolism and higher orders of significance: *P <0.05; **P <0.01; ***P <0.001; ns, not
statistically significant. The central lab of the University Hospital of Heidelberg provides precise values for C-reactive protein (CRP) beginning from 2 mg/L. Lower CRP
values are simply denoted less than 2.0 mg/L. For statistical analyses, all values less than 2.0 mg/L were put on a level of 2.0 mg/L. Precise values for PCT are available
beginning from 0.05 μg/L. Lower PCT values are simply denoted less than 0.05 μg/L. For statistical analyses, all values less than 0.05 μg/L were put on a level of 0.05 μg/L.
IL-6, interleukin-6; PCT, procalcitonin; sCD14-ST, soluble CD14 subtype; TAC, total antioxidant capacity.
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isolates, Gram-negative isolates, both, and suspected in-
fection without any microbiological finding) (data not
shown).
Methylglyoxal-derived carbonyl stress in human sepsis –
Relevance for the progression of the disease?
Within a 28-day and 90-day observation period, plasma
levels of MG at sepsis onset were significantly higher
in non-survivors than in the corresponding survivors
(Additional file 3: Figure S1a and Additional file 4:
Figure S2a). Accordingly, plasma levels of MG proved
to be an early predictor for survival in patients withFigure 2 Diagnostic value of methylglyoxal (MG), C-reactive protein (
subtype (sCD14-ST) for identification of patients with sepsis. Receiver
line), IL-6 (tight alternating dashed line), CRP (short dashed line), PCT (wide
with septic shock at sepsis onset (S/T0, n = 60) and postoperative controlsseptic shock (sepsis onset: ROC-AUC 0.710; cutoff:
591.8 nM→ sensitivity: 0.700; 1-specificity: 0.300 for
28-day survival; ROC-AUC 0.686; cutoff: 568.4 nM→
sensitivity: 0.655; 1-specificity: 0.308 for 90-day sur-
vival) (Additional file 3: Figure S1b and Additional file 4:
Figure S2b). In contrast, plasma levels of MG did not dif-
fer significantly between patients with sepsis-associated
organ failures—for example, acute liver failure, acute renal
failure, and acute respiratory distress syndrome—in com-
parison with those septic patients with unimpaired organ
function (data not shown). One main effect of MG is the
post-translational modification of proteins to form AGEs.
Accordingly, the levels of plasma MG-AGEs reached theirCRP), procalcitonin (PCT), interleukin-6 (IL-6), and soluble CD14
operating characteristic curves for plasma levels of MG (continuous
alternating dashed line), and sCD14-ST (long dashed line) in patients
24 hours after major abdominal surgery (P/T2, n = 30).
Table 4 Diagnostic value of methylglyoxal, C-reactive protein, procalcitonin, interleukin-6, and soluble CD14 subtype
for identification of patients with sepsis
Parameter AUC (S/T0 vs. P/T2) Cutoff Sensitivity 1-Specificity Results of pairwise comparisons
MG, nM 0.993 281.1 0.912 0.000
CRP, mg/L 0.791 152.8 0.667 0.148 <0.001***
PCT, μg/L 0.844 1.46 0.772 0.222 0.002**
IL-6, pg/mL 0.898 401.0 0.737 0.037 0.007**
sCD14-ST, pg/mL 0.832 825 0.912 0.333 <0.001***
Receiver operating characteristic (ROC) analysis was performed with suitable parameters in order to create cutoff values to determine the diagnostic value of each
parameter with regard to the diagnosis of sepsis (S/T0 versus P/T2). Area under the curve (AUC) comparisons of the related ROC curves refer to pairwise
comparisons of each parameter with MG. With regard to symbolism and higher orders of significance: **P <0.01; ***P <0.001. CRP, C-reactive protein; IL-6,
interleukin-6; MG, methylglyoxal; ns, not statistically significant; PCT, procalcitonin; sCD14-ST, soluble CD14 subtype.
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developed septic shock. However, plasma levels of MG-
AGEs failed to be significantly higher in patients with sep-
tic shock compared with healthy volunteers. In contrast,
plasma levels of MG-AGEs were significantly elevated in
patients with septic shock in comparison with postopera-
tive controls at 24 hours (Figure 3a and 3b).Methylglyoxal-derived carbonyl stress in human sepsis -
a consequence of increased methylglyoxal formation?
Blood sugar levels and the corresponding rate of glycoly-
sis were hypothesized to have a relevant influence on
plasmatic MG levels. Accordingly, patients with septic
shock and postoperative controls showed significantly
increased blood sugar levels over the entire study period
in comparison with healthy volunteers (Table 3). How-
ever, there was only a weak correlation between plasma
levels of MG and blood sugar levels (r = 0.139) in all
study groups, implicating the contribution of other fac-
tors (for example, oxidative stress) to the measured in-
creased plasma levels of MG than solely hyperglycemia.
Healthy volunteers were shown to experience a low
grade of oxidative stress, as indirectly assessed by plasma
TAC. In contrast, postoperative controls already showed
increased levels of oxidative stress prior to surgery (P/T0),
which further increased over time after the surgical pro-
cedure (P/T1, P/T2). Compared with both control groups,
patients with septic shock were found to have the highest
level of oxidative stress within 24 hours after sepsis onset
(S/T0, S/T1) (Table 3) and plasma TAC was found to posi-
tively correlate with MG plasma levels (r = 0.348) in all
study groups.Methylglyoxal-derived carbonyl stress in human sepsis -
a consequence of inhibited methylglyoxal detoxification?
In comparison with healthy volunteers, expression of
GLO-1, the key enzyme of the MG detoxification path-
way, was shown to be significantly reduced in patients
with septic shock within the first 24 hours after sepsis
onset (S/T0, S/T1) (Figure 4).Discussion
In this study, MG was identified as a marker for moni-
toring the onset, development, and remission of sepsis.
It was found to be more useful than routine diagnostic
markers, such as CRP, PCT, IL-6, and sCD14-ST. This
finding is of great interest, as it has been suggested that
the currently used biomarkers for sepsis do not have ei-
ther the specificity or sensitivity to be routinely used in
clinical practice [17].
The major source of endogenous MG is from the non-
enzymatic degradation of the triosephosphate intermedi-
ates within glycolysis. Under conditions of increased
glycolytic flux, such as hyperglycemia (a symptom often
observed in patients with sepsis), it would be safe to as-
sume that there should be an increase in MG produc-
tion. In this study, blood sugar levels were significantly
elevated in patients with septic shock. Measured plasma
MG in these patients was also elevated, but only a weak
correlation with blood glucose levels could be shown.
This would suggest that there are other factors contrib-
uting to the measured increased plasma levels of MG
than only hyperglycemia.
In this study, patients with septic shock characteristic-
ally have an increased state of oxidative stress and this
correlates positively with plasma MG levels, suggesting
that a relationship exists between these two forms of
metabolic stress. GLO-1, the major pathway for detoxifi-
cation of MG, is a glutathione (GSH)-dependent enzyme
[18]. Previous studies have shown that under conditions
of oxidative stress, both GSH and nicotinamide-adenine-
dinucleotide-phosphate-hydrate (NADPH) are depleted,
which in turn decreases the in situ activity of GLO-1
[19], thereby increasing the concentration of MG. The
loss of essential cofactors in a situation of increased oxi-
dative stress could therefore be one explanation for the
increased plasma MG observed in the patients with sep-
sis. However, it was also found that patients with sepsis
syndrome had a significant reduction in the expression
of mononuclear GLO-1, suggesting that patients with
sepsis are more susceptible to the accumulation of MG
through the loss of the GLO-1 rather than the loss of an
Figure 3 Methylglyoxal-derived advanced glycation end product (MG-AGE) formation in different inflammatory settings in humans.
(a) Comparisons of plasmatic MG-AGE formation in healthy volunteers (n = 30, white bar) and patients with septic shock (n = 60, white-spotted
bars in black color). Plasma levels of MG-AGEs in patients with septic shock are presented at sepsis onset (S/T0) and 24 hours (S/T1) and 4 days
(S/T2) later. Plasma measurements of MG-AGEs in healthy volunteers were performed once (V/T0). Data in bar charts are presented as medians
and 95% confidence intervals (CIs). With regard to symbolism and higher orders of significance: *P <0.05; ***P <0.001. Asterisks refer to pairwise
comparisons between healthy volunteers and patients with septic shock at the presented time points. (b) Comparisons of plasma MG-AGE formation in
postoperative controls following major abdominal surgery (n = 30, white-striped bars in black color) and patients with septic shock (n = 60, white-spotted
bars in black color). Plasma levels of MG-AGEs in patients with septic shock are presented at sepsis onset (S/T0) and 24 hours (S/T1) later. Plasma
measurements of MG-AGEs in postoperative controls are presented immediately after the end of the surgical procedure (P/T1) and 24 hours afterwards
(P/T2). Data in bar charts are presented as medians and 95% CIs. With regard to symbolism and higher orders of significance: **P <0.01; ***P <0.001.
ns, not statistically significant.
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gagement of the receptor for advanced glycation end
products (RAGE) by inflammatory mediators, such as
carboxylmethyl-lysine (CML) and high-mobility group
box protein-1 (HMGB1), can reduce expression of
GLO-1 [20]. In this study, the cell-surface expression of
RAGE was increased in the monocytes of patients withseptic shock; however, there was also a significant re-
duction in the plasma concentration of the classic
RAGE ligands (data not shown). It has also been pro-
posed that hyperglycemic conditions, such as those ob-
served in diabetes, can directly reduce GLO-1 activity.
However, the underlying mechanism for this effect re-
mains unclear [21].
Figure 4 Methylglyoxal-detoxifying capacity in different
inflammatory settings in humans. Glyoxalase-1 (GLO-1) expression
in peripheral blood mononuclear cells of patients with septic shock
compared with healthy volunteers is shown. Samples from 11 patients
with septic shock—at onset (S/T0) and 24 hours (S/T1) later—and 11
healthy volunteers (V/T0) were analyzed by quantitative reverse
transcription-polymerase chain reaction. Dotted horizontal lines
represent the minimum and maximum change in cycle threshold (ΔCt)
values of healthy volunteers, and solid lines shows the median
accordingly. With regard to symbolism and higher orders of significance:
**P <0.01. ns, not statistically significant.
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translational modification of proteins to form AGEs
[22,23]. This study could show that the concentration of
MG-AGEs in plasma paralleled the levels of MG and
that the highest concentrations were observed 24 hours
after the onset of sepsis. This may simply reflect a
cause-and-effect relationship in the plasma; however, it
may also indicate an increased turnover of MG-modified
or damaged proteins within the tissue [6]. Such modified
proteins are degraded by cellular proteolysis, releasing
not only modified peptides but also the modified amino
acid, which is eventually excreted in the urine [6].
Several studies have shown that MG-derived hydroimi-
dazolone (MG-H1) [24], the adduct formed from MG
modification of arginine, is the major quantitative modi-
fied adduct excreted in humans and rats [25,26]. In-
creased excretion of this modified product, particularly
in diabetes mellitus, is associated with the development
and progression of complications, such as neuropathy,
nephropathy, and retinopathy [9,27-30]. It has also been
shown that MG-AGEs, specifically MG-H1, can interact
with RAGE. Monocytes can bind, internalize, and degrade
albumin which has been minimally modified by MG, lead-
ing to synthesis and secretion of pro-inflammatory media-
tors such as IL-1β, macrophage colony-stimulating factor,and tumor necrosis factor-alpha. It has been suggested
that this binding is mediated by RAGE [31-35], making it
possible that the high circulating levels of MG-AGE pro-
teins found in patients with sepsis could activate circulat-
ing monocytes by ligating RAGE. This may result in the
downregulation of GLO-1 and the induction of the
pro-inflammatory phenotype observed in patients with
septic shock. Further in vitro studies using MG-
modified proteins, modified to a similar extent as those
observed in patients with sepsis, are required to con-
firm this observation.
The findings of increased MG and MG protein dam-
age in sepsis suggest that MG metabolism is an import-
ant and generally overlooked biochemical pathway for
the induction of cellular dysfunction or inflammation (or
both) in sepsis. Furthermore, prevention of MG overload
might represent a new therapeutic option in sepsis. Un-
fortunately, there are currently no MG scavengers ap-
proved for clinical use. As in diabetes, tight blood
glucose control in patients with sepsis may offer a strat-
egy for reducing the amount of MG accumulation. Ac-
cordingly, recent clinical guidelines for the treatment of
sepsis have recommended that blood glucose levels
should be maintained at not more than 180 mg/dL [36].
An alternative treatment strategy could be to increase
GLO-1 activity. It has been shown in vitro that GLO-1
transcription is regulated by the antioxidant transcrip-
tion factor nuclear factor (erythroid-derived 2)-like 2
(Nrf2) [37]. Activation of this transcription factor by
isothiocyanates, such as sulphoraphane, can lead to in-
creased GLO-1 activity and decreased MG and MG-
derived AGEs [38]. Such compounds are found in high
abundance in cruciferous vegetables. However, the effect
of such treatment in vivo remains unknown and requires
further investigation to determine whether it would be
effective in acute illnesses such as sepsis.
Further investigations are required to determine whether
the diagnostic and prognostic value of MG can be con-
firmed and validated in a large study cohort. Moreover, to
link the clinical observations of our study to functional
implications, it needs to be evaluated in vitro, whether
MG modifications are responsible for the cellular dysfunc-
tion or inflammation (or both) observed in sepsis. Critical
to this process would be to identify the cellular targets in-
volved in this modification. It could already be shown that
mitochondrial proteins are particularly susceptible to
modification by MG [39]. The ELISA-based method used
to detect MG-AGEs in this study is unable to differentiate
whether the MG-AGEs measured are complete proteins,
peptides, or the free amino acids. In future studies, the
measurement of both MG and MG-AGEs should be
performed by using the gold-standard technique of stable
isotope dilution, liquid chromatography tandem mass
spectroscopy, which could provide robust identification,
Figure 5 Mechanism of methylglyoxal and methylglyoxal-derived advanced glycation end products driven cell dysfunction or
inflammation or both in human sepsis. DHAP, dihydroxyacetone phosphate; F-1,6-bisP, fructose-1,6-bisphosphate; F6P, fructose 6-phosphate;
G6P, glucose 6-phosphate; GA3P, glyceraldehyde 3-phosphate; GSH, glutathione; RAGE, receptor for advanced glycation end products.
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both) modified by MG [26,40].
Conclusions
The role of RCS, such as MG, has generally been over-
looked in the context of the sepsis syndrome. In this
study, MG was identified as a better marker for the
identification of patients with sepsis in comparison with
routine diagnostic markers. Furthermore, MG was shown
to be an early predictor for survival in patients with septic
shock. It is hypothesized that in sepsis, increased glucose
metabolism resulting from acute hyperglycemia leads to
increased production of MG and MG-AGEs. Activation of
RAGE by MG-AGEs leads to the downregulation of
GLO-1, and a positive feedback loop then leads to further
accumulation of MG as well as the transcription of pro-
inflammatory genes. The modification of different (mito-
chondrial) proteins by MG could lead to increased
oxidative stress, further enhancing the MG-activated
pathways of cellular dysfunction and inflammation
(Figure 5). Further studies are required to determine the
extent of MG modification in sepsis and its relative im-
portance to the progression and remission of the condi-
tion and whether targeting this pathway would be of
therapeutic benefit to the patient.
Key messages
 MG was identified as a better biomarker than the
established routine markers (for example, CRP, PCT,IL-6, and sCD14-ST) for the identification of
patients with sepsis.
 MG was shown to be an early predictor for survival
in patients with septic shock.
 The implementation of MG measurements in
routine diagnostics of patients with suspected sepsis
should therefore be taken into consideration.
 The relative importance of MG to the progression
and remission of septicemia, and whether targeting
MG-derived carbonyl stress would be of therapeutic
benefit to the patient, needs to be further evaluated.Additional files
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